In an industry drowning in noise, Interimarketing has carved a $7.5M niche by becoming the silent partner for life science companies that need more than just press releases—they need narrative architecture.

"They're not selling media coverage—they're selling credibility in an industry where trust is the ultimate currency."

What's fascinating is their digital footprint—or lack thereof. With zero reported monthly visits and no organic keywords, Interimarketing operates as a stealth operator. This isn't a bug; it's a feature. They're not building a public-facing brand for founders to discover—they're building a private network where referrals and reputation matter more than SEO. In biotech, where deals are relationship-driven, this makes perfect sense.

• Founder Meghan O'Sullivan likely still runs client relationships directly—this isn't a faceless agency
• No funding rounds means they're either bootstrapped or profitable—no investor pressure to scale recklessly
• The absence of public traffic data suggests they're referral-only, which is the ultimate validation in biotech
• Their tech stack is modern but not flashy—built for function over flash